Drug – bio-affecting and body treating compositions – Immunoglobulin – antiserum – antibody – or antibody fragment,... – Monoclonal antibody or fragment thereof
Reexamination Certificate
2007-01-23
2007-01-23
Gambel, Phillip (Department: 1644)
Drug, bio-affecting and body treating compositions
Immunoglobulin, antiserum, antibody, or antibody fragment,...
Monoclonal antibody or fragment thereof
C424S130100, C424S133100, C424S134100, C424S141100, C424S142100, C424S154100, C530S387100, C530S388100, C530S388150, C530S388200, C530S388220, C530S388700, C530S388750
Reexamination Certificate
active
10625105
ABSTRACT:
Immunization of human antibody-producing transgenic mice, which have been created using genetic engineering techniques, with AILIM molecule as an antigen resulted in various human monoclonal antibodies capable of binding to AILIM and capable of controlling a variety of biological reactions (for example, cell proliferation, cytokine production, immune cytolysis, cell death, induction of ADCC, etc.) associated with AILIM-mediated costimulatory signal (secondary signal) transduction. Furthermore, it has been revealed that the human monoclonal antibody is effective to treat and prevent various diseases associated with AILIM-mediated costimulatory signal transduction, being capable of inhibiting the onset and/or advancement of the diseases.
REFERENCES:
patent: 5484892 (1996-01-01), Tedder et al.
patent: 5506126 (1996-04-01), Seed et al.
patent: 5521288 (1996-05-01), Linsley et al.
patent: 5747461 (1998-05-01), Markov
patent: 5770197 (1998-06-01), Linsley et al.
patent: 5914112 (1999-06-01), Bednar et al.
patent: 6075181 (2000-06-01), Kucherlapati et al.
patent: 6451305 (2002-09-01), Boussiotis et al.
patent: 6531505 (2003-03-01), Xu et al.
patent: 2002/0115831 (2002-08-01), Tamatani et al.
patent: 2002/0156242 (2002-10-01), Tamatani et al.
patent: 2002/0164697 (2002-11-01), Coyle et al.
patent: 2002/0177191 (2002-11-01), Kroczek
patent: 2002/0182667 (2002-12-01), Kroczek
patent: 13320/99 (1999-04-01), None
patent: 2293666 (1998-12-01), None
patent: 19821060 (1999-04-01), None
patent: 0984023 (2000-03-01), None
patent: 1 125 585 (2001-08-01), None
patent: 5-72204 (1993-03-01), None
patent: 11-228442 (1999-08-01), None
patent: 2000-154151 (2000-06-01), None
patent: WO 89/06138 (1989-07-01), None
patent: WO 94/11499 (1994-05-01), None
patent: WO 95/33770 (1995-12-01), None
patent: WO 97/26912 (1997-07-01), None
patent: WO 98/11909 (1998-03-01), None
patent: WO 98/19706 (1998-05-01), None
patent: WO 98/37415 (1998-08-01), None
patent: WO 98/38216 (1998-09-01), None
patent: WO 98/45331 (1998-10-01), None
patent: WO 99/15553 (1999-04-01), None
patent: WO 00/19988 (2000-04-01), None
patent: WO 00/46240 (2000-08-01), None
patent: WO 00/67788 (2000-11-01), None
patent: WO 01/08700 (2001-02-01), None
patent: WO 01/12658 (2001-02-01), None
patent: WO 01/15732 (2001-03-01), None
patent: WO 01/18022 (2001-03-01), None
patent: WO 01/21796 (2001-03-01), None
patent: WO 01/32675 (2001-05-01), None
patent: WO 01/64704 (2001-09-01), None
patent: WO 01/87981 (2001-11-01), None
patent: WO 02/44364 (2002-06-01), None
patent: WO 02/70010 (2002-09-01), None
patent: WO 02/76504 (2002-10-01), None
Blazar et al., J. Immunol., 1996, 157: 3250-3259.
Perrin et al., J. Neuroimmunol, 1996, 157: 31-39.
Rudikoff et al., Proc. Natl. Acad. Sci. USA, 1982, 79: 1979-1983.
Panka et al., Proc. Natl. Acad. Sci. USA, 1988, 85: 3080-3084.
Chaouat et al., J. Immunol., 1995, vol. 154, pp. 4261-4268.
Aicher et al., “Characterization of Human Inducible Costimulator Ligand Expression and Function,” J. Immunol., 164(9):4689-4696 (2000).
Bajorath, “A molecular model of inducible costimulator protein and three-dimensional analysis of its relation to the CD28 family of T cell-specific costimulatory receptors,” J. Mol. Model 5:169-176 (1999).
Beier et al., “Induction, binding specificity and function of human ICOS,” Eur. J. Immunol., 30(12):3707-3717 (2000).
Brodie et al., “LICOS, a primordial costimulatory ligand?,” Curr. Biol., 10(6):333-336 (2000).
Buonfiglio et al., “Characterization of a novel human surface molecule selectively expressed by mature thymocytes, activated T cells and subsets of T cell lymphomas,” Eur. J. Immunol., 29(9)2863-2874 (1999).
Buonfiglio et al., “The T cell activation molecule H4 and the CD28-like molecule ICOS are identical,” Eur. J. Immunol. 30(12):3463-3467 (2000).
Cameron “Recent advances in transgenic technology” Molecular Biotechnology 7:253-65 (1997).
Chambers, “The expanding world of co-stimulation: the two-signal model revisited,” Trends in Immunology, 22(4):217-223 (2001).
Cocks et al., “A novel receptor involved in T-cell activation,” NATURE, 376:260-263 (1995).
Coyle et al., “The CD28-Related Molecule ICOS Is Required for Effective T Cell-Dependent Immune Responses,” IMMUNITY 13(1):95-105 (2000).
Dong et al., “Cutting Edge: Critical Role of Inducible Costimulator in Germinal Center Reactions,” J. Immunol., 166(6):3659-3662 (2001).
Dong, “ICOS co-stimulatory receptor is essential for T-cell activation and function,” NATURE 409(6816):97-101 (2001).
Gonzalo et al., “Cutting Edge: The Related Molecules CD28 and Inducible Costimulator Deliver Both Unique and Complementary Signals Required for Optimal T Cell Activation,” J. Immunol., 166(1):1-5 (2001).
Guo et al., “Stimulatory Effects of B7-Related Protein-1 on Cellular and Humoral Immune Responses in Mice,” J. Immunol., 166(9):5578-5584 (2001).
Hanzawa et al., “Characteristics of a TTH1 antibody which blocks an unknown adhesion phenomenon,” Proceedings of the Japanese Society for Immunology, vol. 24, Abstract NO. W17-13 (1994) [Original Japanese and English Language Translation].
Heyeck et al., “Developmental regulation of a murine T-cell-specific tyrosine kinase gene, Tsk,” Proc. Natl. Acad. Sci. USA, 90:669-673 (1993).
Houdebine “Production of pharmaceutical proteins from transgenic animals” J. Biotechnol. 34:269-87 (1994).
Hutloff et al., “ICOS is an inducible T-cell co-stimulator structurally and functionally related to CD28,” Nature, 397(6716):263-266 (1999).
Ishikawa et al., “Prediction of the Coding Sequences of Unidentified Human Genes. X. The Complete Sequences of 100 New cDNA Clones for Brain Which Can Code for Large Proteinsin vitro,” DNA Research, 5:169-176 (1998).
Kappel et al. “Regulating gene expression in transgenic animals” Current Opinion in Biotechnology 3:548-53 (1992).
Kopf et al., “Inducible Costimulator Protein (ICOS) Controls T Helper Cell Subset Polarization after Virus and Parasite Infection,” J. Exp. Med., 192(1):53-61 (2000).
Kuchroo et al., “B7-1 and B7-2 costimulatory molecules activate differentially the Th1/Th2 developmental pathways: Application to autoimmune disease therapy,” Cell, 80:707-718 (1995).
Ling et al., “Cutting Edge: Identification of GL50, a Novel B7-Like Protein That Functionally Binds to ICOS Receptor,” J. Immunol., 164(4):1653-1657 (2000).
Mages et al., “Molecular cloning and characterization of murine ICOS and identification of B7h as ICOS ligand,” Eur. J. Immunol., 30(4):1040-1047 (2000).
Marguet et al., “cDNA Cloning for Mouse Thymocyte-activating Molecule,” The Journal of Biological Chemistry, 267(4):2200-2208 (1992).
McAdam et al. (2000) “Mouse inducible costimulatory (ICOS) molecule expression is increased by CD28 costimulation and regulates development of Th2 cells,” FASEB Journal, 14(6):A1169.
McAdam, “ICOS is critical for CD40-mediated antibody class switching,” NATURE 409(6816):102-105 (2001).
McAdam, “Mouse Inducible Costimulatory Molecule (ICOS) Expression Is Enhanced by CD28 Costimulation and Regulates Differentiation of CD4+T Cells,” J. Immunol., 165(9):5035-5040 (2000).
Mueller, “T cells: A proliferation of costimulatory molecules,” Curr. Biol. 10(6):R227-R230 (2000).
Mullins et al. “Expression of the DBA/2J Ren-2 gene int he adrenal gland of transgenic mice”Embo J., 8:4065-72 (1989).
Mullins et al. “Fulminant hypertension in transgenic rats harbouring the mouse Ren-2 gene” NATURE, 344:541-44 (1990).
Mullins et al. “Transgenesis in nonmurine species” Hypertension 22:630-33 (1993).
Niemann “Transgenic farm animals get off the ground” Transgenic Research, 7:73-75 (1998).
Nojima et al., “The 4F9 antigen is a member of the tetr
Hori Nobuaki
Tezuka Katsunari
Tsuji Takashi
Fish & Richardson P.C.
Gambel Phillip
Japan Tobacco Inc.
Ouspenski Ilia
LandOfFree
Methods of treating an inflammatory disorder and prohibiting... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods of treating an inflammatory disorder and prohibiting..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods of treating an inflammatory disorder and prohibiting... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3816417